Cortellis was a drug pipeline tool. ECRI was a device safety database. EvaluatePharma was a biologics tracker. When the market wanted cross-product intelligence, each of them acquired or partnered their way into the adjacent categories. Drug data, device data, and biologics data ended up living in separate schemas, separate teams, separate editorial standards — joined by lossy mappings whenever a customer asked for a cross-product view.

Oushvaa started fresh on a single schema. The canonical entity graph sits at the centre of the platform. Every company, drug, device, and biologic resolves to one stable identifier across all four products. There is no translation layer because there is nothing to translate. A hospital procurement officer searching "Cipla" on Oushvaa Procure sees the same canonical Cipla that DrugIQ uses for the drug catalogue, that MedevIQ uses for device cross-reference, that BiologicsIQ uses for biosimilar tracking.

This means the platform answers questions no incumbent can run in a single query: Every device Stryker sells across nine regulators, with adverse event history. Every drug priced above NPPA ceiling this quarter, manufacturer-cross-linked. Pfizer's biologic pipeline mapped against its CDMO concentration risk. Three companies' worth of data, one join.

The canonical graph isn't a feature. It's the architecture from day one. That choice is the moat.

The platform is closed-by-default. We do not publish open datasets, we do not run a free-tier public API, and we do not expose entity records to anonymous web traffic. Premium intelligence stays premium. Verified academic access opens in 2027 via institutional email verification — not anonymous scraping. The data is audit-grade because the boundaries are.

And the platform is built for global scale. Nine regulators are integrated today: FDA, EMA, MHRA, PMDA, Health Canada, TGA, Swissmedic, ANVISA, EUDAMED. Thirty-five more sit in the schema, lit up as customer entitlements call them. Most healthcare data platforms try to bolt one market onto another and the seams show. Oushvaa built the global architecture from day one, and every market integration plugs into the same canonical layer.

The moat in motion

One canonical entity across drugs, devices, biologics.

Click a company below to see its span across the three intelligence rails. Real entities, real numbers from production data.

DRUGIQ drugs catalogued MEDEVIQ devices across regulators BIOLOGICSIQ biologics in pipeline ROCHE Holding AG · CH
Canonical companies
66,252
Across drugs · devices · biologics
7
MedevIQ cross-link rate
100%
What the platform answers

Questions only this platform can answer.

Real cross-product queries. No incumbent vendor runs these in one place — they would need three companies, three datasets, and a translation layer.

Q1
Show every device Stryker sells globally across 9 regulators — with adverse event history.
2,847 devices · 9 regulators
14,213 AE reports · 38 recalls
→ 4 subsidiary companies linked
MedevIQ Identity Graph
Q2
Find every Indian drug priced above NPPA ceiling today, with manufacturer cross-link.
1,247 brands over ceiling
43 manufacturers implicated
→ 8 in regulator focus this quarter
DrugIQ NPPA live feed
Q3
Cross-reference Pfizer's biologic pipeline against its CDMO concentration risk.
17 biologics in development
4 CDMOs handling 80% of capacity
→ 2 sites with open Form 483
BiologicsIQ Identity Graph

See what the platform can answer for your team.

Investors, pharma BD, regulatory affairs, hospital procurement — different audiences ask different questions. We answer all of them from the same canonical layer.